Dan O’Day’s to-do list for Gilead: Re­cruit a Kite CEO, press the ped­al on next-gen cell ther­a­pies and start buy­ing stuff

Dan O’Day has had a chance to kick the tires at Gilead and take it out for a spin. And he took con­sid­er­able time in his first ap­pear­ance as CEO dur­ing the much-an­tic­i­pat­ed Q1 call on Thurs­day night to ex­plain his strat­e­gy for the bell­wether biotech.

Just don’t look for a lot of ex­cit­ing de­tail from his first per­for­mance, which drew a few muf­fled yawns and mixed re­views from an­a­lysts who have been wait­ing years for Gilead to do some­thing even half as ex­cit­ing as hep C again.

Trans­lat­ing the dry par­lance of biotech fi­nance, which O’Day mas­tered at Roche’s Basel head­quar­ters, he’s de­ter­mined that one of the best ways to stay on top of the cell ther­a­py busi­ness is to bring in a new CEO specif­i­cal­ly for his CAR-T com­pa­ny Kite, where they ex­pect to bring on next-gen tech­nol­o­gy like off-the-shelf ther­a­pies as com­pe­ti­tion breathes down their back.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER